Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewIC 87201
说明： nNOS-PSD95 protein-protein interaction inhibitor; also antinociceptive and antidepressant
化学名： 2-[(1H-Benzotriazol-6-ylamino)methyl]-4,6-dichlorophenol
纯度： ≥99% (HPLC)
生物活性 for IC 87201
IC 87201 is an inhibits binding of the NMDA receptor postsynaptic density protein 95 kDa (PSD95) to nNOS (EC50 = 23.94 μM), while not affecting the PSD95-ErbB4 interaction. Inhibits glutamate-induced cell death in cultured cortical neurons. Exhibits antinociceptive effects in inflammatory pain models in vivo. Also exhibits antidepressant-like activitiy in animal models.
技术数据 for IC 87201
| 分子量 | 309.15 |
| 公式 | C13H10Cl2N4O |
| 储存 | Store at +4°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 866927-10-8 |
| PubChem ID | 11771269 |
| InChI Key | QEHVTUCLCBXQIC-UHFFFAOYSA-N |
| Smiles | OC1=C(C=C(C=C1Cl)Cl)CNC2=CC=C3N=NNC3=C2 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for IC 87201
参考文献 for IC 87201
参考文献是支持产品生物活性的出版物。
Doucet et al (2013) Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology. 38 1575 PMID: 23446451
Lee et al (2015) Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics. Neuropharmacology. 97 464 PMID: 26071110
Florio et al (2009) Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br.J.Pharmacol. 158 494 PMID: 19732061
关键词: IC 87201, IC 87201 supplier, IC87201, postsynaptic, density, protein, 95, PSD95, nNOS, NMDA, protein-protein, interactions, inhibitors, inhibits, binding, antinociceptive, antidepressant, Receptors, 6226, Tocris Bioscience
IC 87201 的评论
目前没有该产品的评论。 Be the first to review IC 87201 and earn rewards!
Have you used IC 87201?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.